MR. DAN CRIPPEN

Lobbying for AMGEN · Manufacture Pharmaceuticals

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $100,000.00 income · posted Feb 18, 2026

Lobbying activity 3

Pharmacy

pharmacy rebates and discounts pharmacy R&D

Economics/Economic Development

pharmacy rebates and discounts

Government Issues

congressional procedure

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.